United States securities and exchange commission logo





                               July 26, 2022

       Erqi Wang
       Chief Executive Officer
       Jin Medical International Ltd.
       No. 33 Lingxiang Road, Wujin District
       Changzhou City, Jiangsu Province
       People   s Republic of China

                                                        Re: Jin Medical
International Ltd.
                                                            Amendment No. 4 to
Registration Statement on Form F-1
                                                            Filed July 15, 2022
                                                            File No. 333-259767

       Dear Mr. Wang:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our April
28, 2022 letter.

       Amendment No. 4 to Registration Statement on Form F-1 filed July 15,
2022

       Cover Page

   1.                                                   We acknowledge your
revised disclosure in response to prior comment 2, which we
                                                        reissue. Please revise
to ensure that all references to control or benefits that accrue to you
                                                        because of the VIE are
limited to a clear description of the conditions you have satisfied
                                                        for consolidation of
the VIE under U.S. GAAP. We note that your disclosure continues to
                                                        refer to the control or
benefits that accrue to you as a result of the VIE, including but not
                                                        limited to the cover
page, pages ii, 1, 2, 86, 87 and 124.
 Erqi Wang
FirstName
Jin MedicalLastNameErqi   Wang
            International Ltd.
Comapany
July       NameJin Medical International Ltd.
     26, 2022
July 26,
Page  2 2022 Page 2
FirstName LastName
Summary of Risk Factors, page 10

2.       We note your revised disclosure in response to prior comment 6, which
we reissue in
         part. Please revise to include specific cross-references for each
summary risk to the more
         detailed discussion of such risks in the prospectus rather than
including page references.
       You may contact Jeanne Baker at 202-551-3691 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Celeste Murphy at 202-551-3257 with any
other questions.



                                                              Sincerely,

                                                              Division of
Corporation Finance
                                                              Office of Life
Sciences
cc:      Ying Li, Esq.